Manufacturers of radiopharmaceuticals from twelve Latin American nations are gathering in Havana from today until November 1 to share their insights into meeting the regulatory standards for these products.
Approximately thirty specialists from the region participate in the conference on this topic, which is being organized by the International Atomic Energy Agency (IAEA).
The primary goal of this event is to showcase the efforts of pharmaceutical companies in the field of radiation to ensure compliance with health standards throughout the registration, licensing, and approval processes, among other aspects.
The event will be attended by Enrique Estrada, a technical expert from the IAEA, specializing in nuclear medicine and imaging.
According to Mayka Guerrero, head of the Specialized Center for Diagnosis and Treatment at the Center for Medical Research Surgery, this workshop will be a chance to learn about the regulatory frameworks for radiopharmaceuticals in Latin America.
Furthermore, it will facilitate the sharing of insights into the difficulties encountered by the radiopharmaceutical sector in meeting regulatory standards.
The International Atomic Energy Agency defines radiopharmaceuticals as pharmaceuticals that contain radioactive forms of chemical elements known as radioisotopes. Depending on the type of radiation emitted by these radioisotopes, they can be utilized for diagnostic or therapeutic purposes in the medical field.
Their applications span from imaging a wide variety of organs, such as the brain, heart, kidneys, and bones, to treating cancer and hyperthyroidism.
